Halozyme Therapeutics Inc (HALO)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 1.37 | 1.56 | 1.32 | 1.21 | 1.51 | 1.41 | 1.32 | 1.47 | 1.39 | 1.15 | 0.92 | 1.66 | 1.51 | 1.54 | 1.25 | 0.96 | 0.71 | 0.59 | 1.05 | 1.13 |
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Working capital turnover | 1.07 | 0.93 | 1.02 | 1.16 | 1.31 | 1.02 | 1.19 | 1.35 | 1.09 | 1.07 | 1.42 | 0.54 | 0.55 | 0.51 | 0.47 | 0.40 | 2.01 | 0.42 | 0.38 | 0.39 |
Halozyme Therapeutics Inc's activity ratios provide insight into how efficiently the company is managing its assets and operations.
1. Inventory Turnover:
- The inventory turnover ratio shows how many times the company's inventory is sold and replaced during a certain period. Halozyme's inventory turnover has fluctuated over the years, ranging from a low of 0.59 to a high of 1.66. Overall, there seems to be some variability in how quickly the company is able to sell its inventory.
2. Receivables Turnover:
- The receivables turnover ratio indicates how efficiently the company is collecting on its credit sales. Unfortunately, data for this ratio is not available, which makes it difficult to assess Halozyme's effectiveness in managing its receivables.
3. Payables Turnover:
- Similar to receivables turnover, payables turnover is not provided in the data. This ratio helps evaluate how long it takes for the company to pay its suppliers, which is essential for understanding its liquidity and relationships with vendors.
4. Working Capital Turnover:
- The working capital turnover ratio evaluates how effectively the company is using its working capital to generate sales. Halozyme's turnover has ranged from 0.38 to 2.01, showing variations in how efficiently the company is utilizing its working capital. A higher turnover indicates better management of working capital in generating revenues.
In conclusion, while the inventory turnover and working capital turnover provide insight into Halozyme's operational efficiency, the lack of data for receivables and payables turnovers limits a comprehensive assessment of the company's overall activity ratios. Tracking these ratios over time can help identify trends and areas for improvement in managing assets and operations.
Average number of days
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 265.61 | 233.77 | 276.13 | 302.62 | 242.12 | 258.29 | 276.67 | 247.52 | 262.34 | 317.38 | 395.70 | 220.34 | 241.69 | 237.31 | 292.46 | 381.64 | 511.28 | 623.39 | 348.56 | 324.09 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Halozyme Therapeutics Inc's Days of Inventory on Hand (DOH) has exhibited fluctuations over the years, with a range from 220.34 days to 623.39 days. The company's inventory turnover rate has varied significantly, indicating differences in inventory management efficiency during the periods analyzed.
On the other hand, no data is available for the Days of Sales Outstanding (DSO) and Number of Days of Payables, suggesting that the company may not have publicly reported this information or that it may not be applicable due to the nature of its operations or accounting practices.
Overall, based on the available data, Halozyme Therapeutics Inc should focus on monitoring and optimizing its inventory levels to improve its operational efficiency and cash flow management. Further information on sales outstanding and payables turnover would provide a more comprehensive view of the company's working capital management.
Long-term
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | — | — | — | — | — | 10.46 | 10.38 | — | 8.74 | 15.83 | 13.14 | 55.39 | 50.41 | 48.29 | 40.71 | 31.96 | 25.26 | 19.47 | 16.16 | 13.99 |
| Total asset turnover | 0.49 | 0.45 | 0.44 | 0.47 | 0.48 | 0.41 | 0.43 | 0.41 | 0.36 | 0.31 | 0.27 | 0.41 | 0.40 | 0.39 | 0.40 | 0.34 | 0.46 | 0.38 | 0.34 | 0.33 |
The fixed asset turnover ratio of Halozyme Therapeutics Inc has shown fluctuating trends over the past few years. It increased steadily from March 2020 to December 2021, indicating that the company was generating more revenue from its fixed assets during that period. However, there was a noticeable decline in the ratio from March 2022 to December 2022, followed by significant fluctuations in subsequent periods, indicating potential inefficiencies in utilizing fixed assets to generate revenue.
On the other hand, the total asset turnover ratio of the company has been erratic, with no clear trend observed over the same period. The ratio fluctuated between a range of 0.27 to 0.49, indicating varying levels of revenue generated per dollar of total assets employed. The inconsistency in this ratio suggests that the company's overall asset utilization efficiency has been unstable and may require further analysis to identify underlying causes.
In summary, while the fixed asset turnover ratio of Halozyme Therapeutics Inc exhibited both growth and decline patterns, reflecting changes in how effectively fixed assets were utilized to generate revenue, the total asset turnover ratio displayed irregular fluctuations, indicating the need for a closer examination of the company's overall asset management and operational efficiency.